Description: High affinity, selective AT1 antagonist
Alternative Names: CGP 48933
Chemical Name: (S)-3-methyl-2-[N-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)pentanamido]butanoic acid
Purity: ≥99% (HPLC)
Biological Activity
Technical Data
Solubility
Calculators
Datasheets
References
Biological Activity
High affinity AT1 receptor antagonist (Ki = 2.38 nM). Displays 30,000-fold selectivity over AT2 receptors. Inhibits angiotensin II-induced release of aldosterone in vitro. Orally active.
Compound Libraries
Valsartan is also offered as part of the
Tocriscreen Plus and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
Solvent
Max Conc. mg/mL
Max Conc. mM
Solubility
DMSO
43.55
100
Preparing Stock Solutions
The following data is based on the product molecular weight 435.52. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass
1 mg
5 mg
10 mg
1 mM
2.3 mL
11.48 mL
22.96 mL
5 mM
0.46 mL
2.3 mL
4.59 mL
10 mM
0.23 mL
1.15 mL
2.3 mL
50 mM
0.05 mL
0.23 mL
0.46 mL
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets
Certificate of Analysis / Product Datasheet
Safety Datasheet
Select another language:
View SDS
References
References are publications that support the products' biological activity.
Criscioneet al (1993) Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br.J.Pharmacol. 110 761 PMID: 8242249
Wexleret al (1996) Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J.Med.Chem. 39 625 PMID: 8576904
Hanafyet al (2008) Effects of angiotensin II blockade on inflammation-induced alterations of pharmacokinetics and pharmacodynamics of calcium channel blockers. Br.J.Pharmacol. 153 90 PMID: 17965735